Packaging and Delivery of Asthma Therapeutics.
Bryan J MathisMisa KusumotoAlexander ZaboronokYuji HiramatsuPublished in: Pharmaceutics (2021)
Asthma is a life-altering, chronic disease of heterogenous origin that features a complex interplay of immune and environmental signaling. Although very little progress has been made in prevention, diverse types of medications and delivery systems, including nanoscale systems, have been or are currently being developed to control airway inflammation and prevent exacerbations and fibrosis. These medications are delivered through mechanical methods, with various inhalers (with benefits and drawbacks) existing, and new types offering some variety in delivery. Of particular interest is the progress being made in nanosized materials for efficient penetration into the epithelial mucus layer and delivery into the deepest parts of the lungs. Liposomes, nanoparticles, and extracellular vesicles, both natural and synthetic, have been explored in animal models of asthma and have produced promising results. This review will summarize and synthesize the latest developments in both macro-(inhaler) and micro-sized delivery systems for the purpose of treating asthma patients.
Keyphrases
- chronic obstructive pulmonary disease
- lung function
- allergic rhinitis
- end stage renal disease
- cystic fibrosis
- ejection fraction
- newly diagnosed
- drug delivery
- chronic kidney disease
- small molecule
- prognostic factors
- risk assessment
- peritoneal dialysis
- mass spectrometry
- atomic force microscopy
- climate change
- drug release
- liver fibrosis